Global Gene Modifying Immunotherapy for Blood Cancer Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 CAR T-cell Therapy
  • 1.4.3 TCR T-cell Therapy
• 1.5 Market by Application
  • 1.5.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2025)
  • 1.5.2 Acute Lymphocytic Leukemia
  • 1.5.3 Chronic Lymphocytic Leukemia
  • 1.5.4 B Cell Lymphoma
  • 1.5.5 Multiple Myeloma
  • 1.5.6 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size
• 2.2 Gene Modifying Immunotherapy for Blood Cancer Growth Trends by Regions
  • 2.2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions (2019-2025)
  • 2.2.2 Gene Modifying Immunotherapy for Blood Cancer Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by by Players
  • 3.1.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue by by Players (2014-2019)
  • 3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio (CR5 and HHI)
• 3.2 Gene Modifying Immunotherapy for Blood Cancer Key Players Head office and Area Served
• 3.3 Key Players Gene Modifying Immunotherapy for Blood Cancer Product/Solution/Service
• 3.4 Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2014-2019)
• 4.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2014-2019)

5 North America

• 5.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
• 5.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in North America
• 5.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
• 5.4 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

6 Europe

• 6.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
• 6.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Europe
• 6.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
• 6.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

7 China

• 7.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
• 7.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in China
• 7.3 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
• 7.4 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

8 Japan

• 8.1 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
• 8.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Japan
• 8.3 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
• 8.4 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
• 9.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Southeast Asia
• 9.3 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
• 9.4 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

10 India

• 10.1 India Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
• 10.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in India
• 10.3 India Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
• 10.4 India Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

11 Central & South America

• 11.1 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
• 11.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Central & South America
• 11.3 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
• 11.4 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

12 International Players Profiles

• 12.1 Novartis
  • 12.1.1 Novartis Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
  • 12.1.4 Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019))
  • 12.1.5 Novartis Recent Development
• 12.2 Kite Pharma
  • 12.2.1 Kite Pharma Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
  • 12.2.4 Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
  • 12.2.5 Kite Pharma Recent Development
• 12.3 Juno Therapeutics
  • 12.3.1 Juno Therapeutics Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
  • 12.3.4 Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
  • 12.3.5 Juno Therapeutics Recent Development
• 12.4 Cellectis
  • 12.4.1 Cellectis Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
  • 12.4.4 Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
  • 12.4.5 Cellectis Recent Development
• 12.5 Ziopharm Oncology
  • 12.5.1 Ziopharm Oncology Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
  • 12.5.4 Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
  • 12.5.5 Ziopharm Oncology Recent Development
• 12.6 Celyad
  • 12.6.1 Celyad Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
  • 12.6.4 Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
  • 12.6.5 Celyad Recent Development
• 12.7 Bluebird Bio
  • 12.7.1 Bluebird Bio Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
  • 12.7.4 Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
  • 12.7.5 Bluebird Bio Recent Development
• 12.8 Bellicum Pharmaceuticals
  • 12.8.1 Bellicum Pharmaceuticals Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
  • 12.8.4 Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
  • 12.8.5 Bellicum Pharmaceuticals Recent Development
• 12.9 Mustang Bio
  • 12.9.1 Mustang Bio Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
  • 12.9.4 Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
  • 12.9.5 Mustang Bio Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Product (2019-2025)
• 13.2 Market Size Forecast by Application (2019-2025)
• 13.3 Market Size Forecast by Regions
• 13.4 North America
• 13.5 Europe
• 13.6 China
• 13.7 Japan
• 13.8 Southeast Asia
• 13.9 India
• 13.10 Central & South America

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer